Literature DB >> 21186331

High plasma concentrations of transforming growth factor-β and tissue inhibitor of metalloproteinase-1: potential non-invasive predictors for electroanatomical remodeling of atrium in patients with non-valvular atrial fibrillation.

Sook Kyoung Kim1, Jae Hyung Park, Jong Youn Kim, Jong Il Choi, Boyoung Joung, Moon-Hyoung Lee, Sung Soon Kim, Young-Hoon Kim, Hui-Nam Pak.   

Abstract

BACKGROUND: The degree of electroanatomical remodeling of the left atrial (LA) affects the clinical outcome after rhythm control of atrial fibrillation (AF). Our hypothesis was that plasma concentrations of transforming growth factor (TGF)-β and tissue inhibitor of metalloproteinase (TIMP)-1 reflect LA voltage and structural remodeling in patients with non-valvular AF. METHODS AND
RESULTS: In the study, 242 patients (male 79.4%, 55.1 ± 11.0 years old) with AF (155 paroxysmal AF, 87 persistent AF) underwent catheter ablation. Pre-ablation plasma concentrations of TGF-β and TIMP-1 and the degree of electroanatomical remodeling quantified by LA voltage map (NavX) and 3D-CT were evaluated. The mean LA voltage and volume were compared in patients with high TGF-β (≥10.0 ng/ml, H-TGF) vs. low TGF-β (<10.0 ng/ml, L-TGF) and high TIMP-1 (≥1.1 ng/ml, H-TIMP) vs. low TIMP-1 (<1.1 ng/ml, L-TIMP). Patients with H-TGF had lower mean LA voltage (P=0.014) and greater LA volume (P=0.022), particularly, posterior venous LA volume (P=0.005) than those with L-TGF. In patients with H-TIMP, the mean LA voltage (P=0.019) was lower than those with L-TIMP. LA volume was significantly higher (P<0.001) in patients with ejection fraction ≤58% than those with >58%.
CONCLUSIONS: In patients with non-valvular AF, high plasma concentrations TGF-β and TIMP-1 and low ejection fraction were closely related with electroanatomical remodeling of LA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21186331     DOI: 10.1253/circj.cj-10-0758

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  17 in total

1.  Circulating fibrosis biomarkers and risk of atrial fibrillation: The Cardiovascular Health Study (CHS).

Authors:  Michael A Rosenberg; Marlena Maziarz; Alex Y Tan; Nicole L Glazer; Susan J Zieman; Jorge R Kizer; Joachim H Ix; Luc Djousse; David S Siscovick; Susan R Heckbert; Kenneth J Mukamal
Journal:  Am Heart J       Date:  2014-02-26       Impact factor: 4.749

2.  Triggered firing and atrial fibrillation in transgenic mice with selective atrial fibrosis induced by overexpression of TGF-β1.

Authors:  Eue-Keun Choi; Po-Cheng Chang; Young-Soo Lee; Shien-Fong Lin; Wuqiang Zhu; Mitsunori Maruyama; Michael C Fishbein; Zhenhui Chen; Michael Rubart-von der Lohe; Loren J Field; Peng-Sheng Chen
Journal:  Circ J       Date:  2012-03-22       Impact factor: 2.993

3.  TGF-β1 and TIMP-4 regulate atrial fibrosis in atrial fibrillation secondary to rheumatic heart disease.

Authors:  Yu Sun; Zi-Yang Huang; Zhen-Hua Wang; Cui-Ping Li; Xian-Liang Meng; Yun-Jiao Zhang; Feng Su; Nan Ma
Journal:  Mol Cell Biochem       Date:  2015-05-14       Impact factor: 3.396

Review 4.  Circulating Biomarkers Predictive of Postoperative Atrial Fibrillation.

Authors:  Mohit K Turagam; Mahek Mirza; Paul H Werner; Jasbir Sra; David C Kress; A Jamil Tajik; Arshad Jahangir
Journal:  Cardiol Rev       Date:  2016 Mar-Apr       Impact factor: 2.644

Review 5.  The Atrium in Atrial Fibrillation - A Clinical Review on How to Manage Atrial Fibrotic Substrates.

Authors:  Pedro Silva Cunha; Sérgio Laranjo; Jordi Heijman; Mário Martins Oliveira
Journal:  Front Cardiovasc Med       Date:  2022-07-04

6.  Higher serum sST2 is associated with increased left atrial low-voltage areas and atrial fibrillation recurrence in patients undergoing radiofrequency ablation.

Authors:  Jiali Fan; Yuan Li; Qing Yan; Wenhuan Wu; Pan Xu; Lu Liu; Chunhong Luan; Juanli Zhang; Qiangsun Zheng; Jiahong Xue
Journal:  J Interv Card Electrophysiol       Date:  2022-02-17       Impact factor: 1.759

7.  Increased levels of inflammatory and extracellular matrix turnover biomarkers persist despite reverse atrial structural remodeling during the first year after atrial fibrillation ablation.

Authors:  Naoko Sasaki; Yasuo Okumura; Ichiro Watanabe; Hiroaki Mano; Koichi Nagashima; Kazumasa Sonoda; Rikitake Kogawa; Kimie Ohkubo; Toshiko Nakai; Atsushi Hirayama
Journal:  J Interv Card Electrophysiol       Date:  2014-02-20       Impact factor: 1.900

8.  Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1.

Authors:  Dolkun Rahmutula; Gregory M Marcus; Emily E Wilson; Chun-Hua Ding; Yuanyuan Xiao; Agnes C Paquet; Rebecca Barbeau; Andrea J Barczak; David J Erle; Jeffrey E Olgin
Journal:  Cardiovasc Res       Date:  2013-04-23       Impact factor: 10.787

Review 9.  [Biomarkers and atrial fibrillation : Prediction of recurrences and thromboembolic events after rhythm control management].

Authors:  Jelena Kornej; Katja Schumacher; Daniela Husser; Gerhard Hindricks
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-05-14

10.  Mitochondrial DNA 4977bp deletion mutation in peripheral blood reflects atrial remodeling in patients with non-valvular atrial fibrillation.

Authors:  Jihei Sara Lee; Young-Guk Ko; Kyoung-Jin Shin; Sook-Kyoung Kim; Jae Hyung Park; Ki-Cheol Hwang; Hui-Nam Pak
Journal:  Yonsei Med J       Date:  2015-01       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.